KU-2285

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558240

CAS#: 121077-11-0

Description: KU-2285 is a potent hypoxic cell radiosensitizer. At less than 100 mg/kg, KU-2285 sensitized SCCVII tumors more than MISO and SR-2508 by fractionated irradiation. KU-2285 entered clinical trials in late 1990s.


Chemical Structure

img
KU-2285
CAS# 121077-11-0

Theoretical Analysis

MedKoo Cat#: 558240
Name: KU-2285
CAS#: 121077-11-0
Chemical Formula: C8H10F2N4O4
Exact Mass: 264.07
Molecular Weight: 264.190
Elemental Analysis: C, 36.37; H, 3.82; F, 14.38; N, 21.21; O, 24.22

Price and Availability

Size Price Availability Quantity
5g USD -2
10mg USD -2
25mg USD -2
50mg USD -2
100mg USD -2
200mg USD -2
500mg USD -2
1g USD -2
2g USD -2
Bulk inquiry

Synonym: KU2285; KU-2285; KU 2285.

IUPAC/Chemical Name: 2,2-difluoro-N-(2-hydroxyethyl)-3-(2-nitro-1H-imidazol-1-yl)propanamide

InChi Key: VOXUFOPZGRTSJY-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H10F2N4O4/c9-8(10,6(16)11-2-4-15)5-13-3-1-12-7(13)14(17)18/h1,3,15H,2,4-5H2,(H,11,16)

SMILES Code: O=C(NCCO)C(F)(F)CN1C=CN=C1[N+]([O-])=O

Appearance: Solid powder

Purity: >98%

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >5 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:         

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 264.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Shibamoto Y, Ohshio G, Hosotani R, Nishimura Y, Manabe T, Imamura M, Abe M. A phase I/II study of a hypoxic cell radiosensitizer KU-2285 in combination with intraoperative radiotherapy. Br J Cancer. 1997;76(11):1474-9. PubMed PMID: 9400944; PubMed Central PMCID: PMC2228186.

2: Shibamoto Y, Takahashi M, Abe M. A phase I study of a hypoxic cell sensitizer KU-2285 in combination with conventional radiotherapy. Radiother Oncol. 1996 Jul;40(1):55-8. PubMed PMID: 8844888.

3: Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Abe M. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation. Jpn J Cancer Res. 1996 Jan;87(1):98-104. PubMed PMID: 8609056.

4: Oya N, Shibamoto Y, Shibata T, Murata R, Iwai H, Sugiyama T, Abe M. KIN-804 vs. KU-2285 as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):595-600. PubMed PMID: 8005822.

5: Iwai H, Matsuno E, Sasai K, Shibamoto Y, Abe M. Radiosensitizing activity and pharmacokinetics of multiple dose administered KU-2285 in peripheral nerve tissue in mice. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):591-4. PubMed PMID: 8005821.

6: Shibata T, Shibamoto Y, Oya N, Sasai K, Murata R, Ishigaki T, Abe M. Comparison of radiosensitizing effect of KU-2285 and SR-2508 at low drug concentrations and doses. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):587-90. PubMed PMID: 8005820.

7: Shibamoto Y, Kitakabu Y, Murata R, Oya N, Shibata T, Sasai K, Takahashi M, Abe M. Reoxygenation in the SCCVII tumor after KU-2285 sensitization plus single or fractionated irradiation. Int J Radiat Oncol Biol Phys. 1994 Jun 15;29(3):583-6. PubMed PMID: 8005819.

8: Oya N, Shibamoto Y, Sasai K, Sugiyama T, Abe M. In vivo radiosensitization efficacy of KU-2285 and etanidazole at clinically relevant low radiation doses. Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1113-9. PubMed PMID: 8262836.

9: Shibamoto Y, Streffer C, Sasai K, Oya N, Abe M. Radiosensitization efficacy of KU-2285, RP-170 and etanidazole at low radiation doses: assessment by in vitro cytokinesis-block micronucleus assay. Int J Radiat Biol. 1992 Apr;61(4):473-8. PubMed PMID: 1349329.

10: Sasai K, Fushiki M, Yukawa Y, Suyama S, Iwai H, Shibamoto Y, Nishimoto S, Takahashi M, Abe M. In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation. Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1231-4. PubMed PMID: 1938521.

11: Sasai K, Nishimoto S, Shimokawa K, Hisanaga Y, Kitakabu Y, Shibamoto Y, Zhou L, Wang J, Takahashi M, Kagiya T, et al. A fluorinated 2-nitroimidazole, KU-2285, as a new hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys. 1991 Jun;20(6):1249-54. PubMed PMID: 1828462.